This morning, Helus Pharma (formerly Cybin) announced a positive topline readout from its first Phase 3 study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD). Here, we provide breaking coverage and rapid analysis. Helus’ Phase 3 program, PARADIGM, trials HLP003 as an adjunctive treatment for MDD in adults who have had an inadequate…





